PMID- 34487089
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20211009
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 92
IP  - 4
DP  - 2021 Sep 2
TI  - A study of isolated hyperglycemia (blood glucose >/=155 mg/dL) at 1-hour of oral 
      glucose tolerance test (OGTT) in patients with beta-transfusion dependent 
      thalassemia (beta-TDT) followed for 12 years.
PG  - e2021322
LID - 10.23750/abm.v92i4.11105 [doi]
LID - e2021322
AB  - OBJECTIVE: Subjects with normal glucose tolerance (NGT) but 1-hour post-load 
      plasma glucose (1-h OGTT) >/= 155 mg/dl (8.6 mmol/L; H-NGT) have an increased risk 
      for developing Type 2 diabetes mellitus (T2DM), determining a new risk factor 
      category with deeper metabolic impairment. The aim of this study was to evaluate 
      the H-NGT as a diagnostic predictor of future dysglycemia in beta-transfusion 
      dependent thalassemia (beta-TDT). Indices of insulin secretion and insulin 
      sensitivity derived at baseline from OGTTs, were also reviewed. STUDY DESIGN AND 
      METHODS: OGTT and indices of insulin secretion and insulin sensitivity, derived 
      at baseline during OGTT, in 17 beta-TDT with H-NGT and 29 beta-TDT with normal OGTT 
      (NGT) and without H-NGT followed for 12 years were studied. RESULTS: H-NGT was 
      associated with decreased insulin sensitivity and progressive deterioration of 
      glucose tolerance. At baseline, serum ferritin and serum alanine aminotransferase 
      (ALT) levels were higher in patients with H-NGT compared to patients with NGT. A 
      strong correlation was observed between ALT and 1-hour plasma glucose value 
      during OGTT in the total group of 36 patients . Compliance to iron chelation 
      therapy was poor in beta-TDT patients with H-NGT. An inverse correlation was found 
      between 1-hour plasma glucose value during OGTT and insulin secretion-sensitivity 
      index-2 (ISSI-2) (r: -0.3298; p: 0.025), between ISSI-2 and ALT (r: -0.3262; p: 
      0.027), and between 1-hour plasma glucose value and ISSI-2 (r: -0.537; p: 0.005) 
      in the whole group of beta-TDT patients enrolled in our study. CONCLUSIONS: This 
      retrospective study displayed that finding an isolated high 1-hour post-load 
      glucose level (>/=155 mg/dL; H-NGT) during the OGTT may serve as a simple biomarker 
      to detect high-risk patients, with chronic liver disease and/or iron overload, 
      who need periodic glycemic surveillance. Measuring the ISSI 2 represented another 
      valuable predictive marker in the assessment of glycemia in these patients.
FAU - De Sanctis, Vincenzo
AU  - De Sanctis V
AD  - Quisisana Hospital, Ferrara. vdesanctis@libero.it.
FAU - Soliman, Ashraf
AU  - Soliman A
AD  - Department of Pediatrics, Division of Endocrinology, Hamad General Hospital, 
      Doha, Qatar and Department of Pediatrics, Division of Endocrinology, Alexandria 
      University Children's Hospital, Alexandria, Egypt. atsoliman56@gmail.com.
FAU - Tzoulis, Ploutarchos
AU  - Tzoulis P
AD  - Department of Diabetes & Endocrinology, Whittington Hospital, University College 
      London, London, UK. ptzoulis@yahoo.co.uk.
FAU - Daar, Shahina
AU  - Daar S
AD  - Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos 
      University, Sultanate of Oman. sf.daar@gmail.com.
FAU - Pozzobon, Gabriella Cinzia
AU  - Pozzobon GC
AD  - IRCCS, San Raffaele Scientific Institute, Milan, Italy. vdesanctis@libero.it.
FAU - Kattamis, Christos
AU  - Kattamis C
AD  - First Department of Paediatrics, National Kapodistrian University of Athens, 
      Greece.. christos.kattamis@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20210902
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/diagnosis
MH  - Glucose Tolerance Test
MH  - Humans
MH  - *Hyperglycemia
MH  - *Insulin Resistance
MH  - Retrospective Studies
MH  - *beta-Thalassemia/complications
PMC - PMC8477110
COIS- Each author declares that he or she has no commercial associations (e.g. 
      consultancies, stock ownership, equity interest, patent/licensing arrangement 
      etc.) that might pose a conflict of interest in connection with the submitted 
      article.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/01/01
CRDT- 2021/09/06 12:16
PHST- 2020/12/10 00:00 [received]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2021/09/06 12:16 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - ACTA-92-322 [pii]
AID - 10.23750/abm.v92i4.11105 [doi]
PST - epublish
SO  - Acta Biomed. 2021 Sep 2;92(4):e2021322. doi: 10.23750/abm.v92i4.11105.